intensity is significantly associated with increased relapse, decreased
disease-free survival (DFS), and decreased overall survival (OS) in acute
myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new
analysis of a phase III randomized clinical trial has shown.
A first-in-class immunoglobulin G4 (IgG4) antibody targeting CD47 has demonstrated durable responses when used in combination with rituximab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or indolent lymphoma.
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.